PTGX

Protagonist Therapeutics Stock Analysis

AI Rating

Low
  • Quality4/10
  • Growth↓ 2/10
  • Value↓ 0/10
Protagonist Therapeutics sales and earnings growth
PTGX Growth
Fair
  • Revenue Y/Y↓ -64.36%
  • EPS Y/Y↓ -301.11%
  • FCF Y/Y↓ -135.16%
Protagonist Therapeutics gross and profit margin trends
PTGX Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -154.90%
  • ROIC 5Y↓ -11.53%
Protagonist Therapeutics net debt vs free cash flow
PTGX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Protagonist Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks